Title : Hyperuric acid is involved in the progression of adriamycin cardiotoxicity
Abstract:
Objective: Based on the phenomenon of elevated blood uric acid in patients with clinical adriamycin cardiac injury, to explore the effect of high uric acid on the progression of adriamycin cardiotoxicity.
Methods: Adriamycin cardiotoxicity mouse model was established by intraperitoneal injection of adriamycin 3.5 mg/kg/3d, and high uric acid + cardiotoxicity mouse model was established by exogenous administration of potassium oxalate combined with yeast extract by gavage on the basis of cardiotoxicity model, to observe the effect of high uric acid on the cardiotoxicity of adriamycin.
Results: Compared with the control group, the cardiotoxic group showed a significant decrease in left ventricular ejection fraction and left ventricular shortening fraction, a significant increase in CTnI, BNP and NT-ProBNP myocardial injury markers, and a significant increase in blood uric acid level when the cumulative dose of adriamycin reached 14mg/kg; compared with the cardiotoxic group, the hyperuricemic+cardiotoxic group had significantly higher blood uric acid levels, significantly lower left ventricular ejection fraction, left ventricular shortening fraction, and higher levels of CTnI, BNP, and NT-ProBNP markers of myocardial injury.
Conclusion: High uric acid can participate in the development of adriamycin cardiotoxicity and maybe exacerbate the cardiac injury condition in adriamycin cardiotoxic mice.
Keywords?Hyperuricemic, Adriamycin, Doxorubicin, Cardiotoxicity.
Audience Take Away Notes:
- Recognizing that high uric acid is indeed an independent risk factor for cardiovascular disease.
- Understanding the involvement of hyperuric acid in the development of adriamycin cardiotoxicity.
- Uric acid lowering may be a new direction in the development of drugs to combat adriamycin cardiotoxicity.
